The Proteomics Drug Development Gap
Proteins, not genes, are the principal active engines of biology, comprising the primary intervention targets for pharmaceuticals. Proteomics thus supersedes Genomics, of all the "Omics" disciplines of Systems Biology, as the most promising generator of information translatable to healthcare. 
Proteomic efforts to date principally utilize Mass Spectrometry data sets to annotate protein sequence and identification to gene databases. Such data sets characterize peptide constituent lists derived from protein fragments. Yet for drugs, the mechanisms of action are often associated with large changes in functional confirmations which can only be characterized with intact bioactive proteins. However, to date the correlation of proteomic sequence annotation to proteomic functional annotation has not been fully developed or commercialized. Particularly in the cases of cancers and neuro-degenerative diseases, the need to differentiate, select and functionally annotate conformational variants is of strategic therapeutic necessity. A new, functional paradigm for Proteomics is needed.
ProFACT's proprietary platform, SeraFILE and its associated prospecting methods, fulfills this purpose. Through the integration of unprecedented advances in separations technology to coincide with data-reporting infrastructure already available, functional proteomic characterizations can be more precisely resolved and annotated.
To better understand SeraFILE™ or its three application areas, click on the links below:
Partnerships and Services
We work collaboratively with our clients to customize applications to their research projects. Protocols developed are transferable to the client if desired. ProFACT maintains a high-throughput functional proteomics laboratory and network of 3rd parties for ancillary data requirements.
ProFACT works with clients on both a partnership and fee-for-service basis. Partnerships typically take the form of a negotiated contribution from both parties, with both participating in the results and discoveries. Fee-for-service relationships are client sponsored research whereby the client enjoys unimpeded, complete and exclusive rights, subject to no further compensation, to exploit all information and discoveries that arise from such research.
Confidentiality: ProFACT will not disclose any information obtained in the course of the services provided to clients without the express consent of the client. Confidentiality Agreements are often executed.
Talk to us about your drug development or system biology requirements. For more information, contact Matthew Kuruc at 732-230-3021 or
mkuruc@profactproteomics.com.
